Psychiatr. pro Praxi, 2003; 4: 177-180

Vplyv antipsychotickej liečby na hmotnosť pacientov

MUDr. Radovan Vaškovský
Psychiatrické oddelenie, Fakultná nemocnica Nitra

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaškovský R. Vplyv antipsychotickej liečby na hmotnosť pacientov. Psychiatr. praxi. 2003;4(4):177-180.

Pomerne širokou oblasťou farmakologickej liečby je skupina antipsychotík, preferenčne používaná v liečbe psychotických porúch. Naším sledovaním pomerne rozsiahlej skupiny 120 pacientov sme získali vlastné skúsenosti so zmenou hmotnosti u pacientov na antipsychotickej liečbe. Potvrdilo sa nám, že pacienti užívajúci atypické antipsychotiká dosahujú výraznejší nárast hmotnosti v porovnaní s klasickými anti­psychotikami. Dané sledovanie nám ponúka prehľadnú skúsenosť s možnou mierou ovplyvnenia hmotnosti u pacientov liečených antipsychotikami, či už tzv. klasickými, alebo novšími a modernejšími - atypickými.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Barak Y. Risperidone defies weight gain in elderly psychotic patients. J Clin Psychiatry 2002; 63: 117-119. Go to original source... Go to PubMed...
    2. Reinstein MJ, Sirotovskaya LA, et al. Effect of Clozapine-Quetiapine Combination Therapy on weight and glycaemic control. Clin. Drug Investigation 1999; 18(2): 99-104. Go to original source...
    3. Malyuk R, Gibson B, Procyshyn RM, Kang N. Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report. Int J. Geriatr. Psychiatry 2002; 17: 326-328. Go to original source... Go to PubMed...
    4. Silverstone T, Smith G, Goodall E. Prevalence of obesity in patients receiving depot antipsychotics. Br.J.Psychiatry 1988; 153: 214-217. Go to original source... Go to PubMed...
    5. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guilines from clinical trials. J Clin Psychiatry 1999; 60 (suppl 10): 31-41.
    6. Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J psychiatry 1992; 149: 689-690. Go to original source... Go to PubMed...
    7. Henderson DC, Cagliero E, Gray C, Nasrallah RS, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am. J. Psychiatry 2000; 157: 975-981. Go to original source... Go to PubMed...
    8. Sussman N. Review of Atypical Antipsychotics and Weight Gain. J Clin Psychiatry 2001; 62: 5-12.
    9. Aronne LJ. Epidemiology, Morbidity and Treatment of Overweight and Obesity. J.Clin Psychiatry 2001; 62: 13-22. Go to original source...
    10. McIntyre RS, Mancini DA, Basile VS. Mechanisms of Antipsychotic-Induced Weight Gain. J Clin Psychiatry 2001; 62: 23-29.
    11. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696. Go to original source... Go to PubMed...
    12. Kurzthaler I, Fleischhacker WW. The clinical implication of weight gain in schizophrenia. J Clin Psychiatry 2001; 62 (suppl 7): 32-37.
    13. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry 2001; 62: 114-116. Go to original source... Go to PubMed...
    14. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J. Clin Psychiatry 2001: 62: 92-100. Go to original source... Go to PubMed...
    15. Brecher M, Rak IW, Westhead EK, et al. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287-292. Go to original source... Go to PubMed...
    16. Svačina Š. Obezita a psychofarmaka. Triton 2002, 130s.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.